[ ]
Международное непатентованное наименование AT-001
Торговое наименование -
Производитель, страна NYU Langone Health, USA
Механизм действия

AT-001 is an aldose reductase inhibitor that has demonstrated potential therapeutic effects on diabetic cardiomyopathy. Given the involvement of the heart in individuals with severe COVID-19 complications, AT-001 is being tested to see how it can impact the cardiac structure, function, and survival of COVID-19 patients.

Публикации COVID-19

Justin CoyleEfehi Igbinomwanhia, et al. A Recovered Case of COVID-19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT-001. JACC Case Rep. 2020 May 3. doi: 10.1016/j.jaccas.2020.04.025.


Angeliki M.Angelidi, Matthew J.Belanger, Christos S.Mantzoros. COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next. Metabolism. 19 April 2020, 154245. DOI: 10.1016/j.metabol.2020.154245. 

Клинические исследования
Название протокола A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection
Дата начала и окончания КИ April 8, 2020 - December 31, 2020
Название организации, проводящей КИ NYU Langone Health
Страны USA
Фаза II
Кол-во пациентов 500